Cora N Sternberg

List of Publications by Citations

330 papers	33,400 citations	73 h-index	181 g-index
356 ext. papers	40,259 ext. citations	8.5 avg, IF	6.61 L-index

#	Paper	IF	Citations
330	Increased survival with enzalutamide in prostate cancer after chemotherapy. *New England Journal of Medicine*, **2012**, 367, 1187-97	59.2	3075
329	Abiraterone and increased survival in metastatic prostate cancer. *New England Journal of Medicine*, **2011**, 364, 1995-2005	59.2	3019
328	Enzalutamide in metastatic prostate cancer before chemotherapy. *New England Journal of Medicine* , **2014**, 371, 424-33	59.2	1892
327	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *New England Journal of Medicine*, **2017**, 376, 1015-1026	59.2	1788
326	Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. *Lancet, The*, **2002**, 360, 103-6	40	1381
325	Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *New England Journal of Medicine*, **2013**, 369, 722-31	59.2	1332
324	Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. *New England Journal of Medicine*, **1997**, 337, 295-300	59.2	1249
323	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncology, The*, **2012**, 13, 983-92	21.7	965
322	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncology, The*, **2015**, 16, 152-60	21.7	856
321	Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. *New England Journal of Medicine*, **1988**, 318, 1414-22	59.2	813
320	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *Journal of Clinical Oncology*, **2016**, 34, 1402-18	2.2	666
319	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. *Lancet Oncology, The*, **2010**, 11, 1066-73	21.7	646
318	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet, The*, **2016**, 387, 545-557	40	630
317	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). *Lancet, The*, **2012**, 380, 2018-27	40	594
316	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 917-927	21.7	580
315	Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. *Cancer*, **1989**, 64, 2448-58	6.4	573
314	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. *New England Journal of Medicine*, **2018**, 378, 2465-2474	59.2	525

313	Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. *Journal of Urology*, **1985**, 133, 403-7	2.5	512
312	Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. *Journal of Clinical Oncology*, **2011**, 29, 2432-8	2.2	349
311	Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. *Journal of Clinical Oncology*, **2014**, 32, 1412-8	2.2	314
310	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *European Urology*, **2018**, 73, 178-211	10.2	313
309	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. *Journal of Clinical Oncology*, **2013**, 31, 3791-9	2.2	310
308	Guidelines on bladder cancer. *European Urology*, **2002**, 41, 105-12	10.2	302
307	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. *New England Journal of Medicine*, **2020**, 383, 1218-1230	59.2	294
306	Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. *Journal of Clinical Oncology*, **2009**, 27, 5431-8	2.2	268
305	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 76-86	21.7	237
304	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. *Lancet Oncology, The*, **2012**, 13, 1210-7	21.7	225
303	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *New England Journal of Medicine*, **2019**, 381, 2506-2518	59.2	219
302	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. *European Urology*, **2019**, 75, 88-99	10.2	216
301	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 286-96	21.7	215
300	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. *Lancet Oncology, The*, **2012**, 13, 827-37	21.7	212
299	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. *Journal of Clinical Oncology*, **2017**, 35, 3916-3923	2.2	204
298	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. *European Urology*, **2017**, 71, 151-154	10.2	202
297	Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. *Clinical Cancer Research*, **2009**, 15, 7421-8	12.9	192
296	Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *European Urology*, **2014**, 66, 120-37	10.2	190

295	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. *Lancet Oncology, The*, **2011**, 12, 211-4	21.7	186
294	Targeted therapies for renal cell carcinoma: review of adverse event management strategies. *Journal of the National Cancer Institute*, **2012**, 104, 93-113	9.7	168
293	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration. *Journal of Clinical Oncology*, **2020**, 38, 3763-3772	2.2	164
292	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. *Journal of Clinical Oncology*, **2016**, 34, 3005-13	2.2	163
291	A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. *European Urology*, **2012**, 62, 523-33	10.2	162
290	Clonal evolution of chemotherapy-resistant urothelial carcinoma. *Nature Genetics*, **2016**, 48, 1490-1499	36.3	161
289	Contemporary role of androgen deprivation therapy for prostate cancer. *European Urology*, **2012**, 61, 11-25	10.2	159
288	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *European Urology*, **2020**, 77, 508-547	10.2	155
287	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. *Lancet Oncology, The*, **2014**, 15, 1147-56	21.7	154
286	Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. *BJU International*, **2010**, 106, 462-9	5.6	145
285	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 509-21	21.7	138
284	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. *European Urology*, **2013**, 63, 58-66	10.2	133
283	Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. *European Urology*, **2009**, 56, 594-605	10.2	123
282	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. *Lancet, The*, **2017**, 390, 2266-2277	40	121
281	Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. *Cancer*, **1991**, 67, 1525-31	6.4	118
280	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 417-25	21.7	116
279	Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. *European Urology*, **2009**, 55, 62-75	10.2	115
278	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. *New England Journal of Medicine*, **2020**, 382, 2197-2206	59.2	114

277	Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. *Journal of the National Cancer Institute*, **2013**, 105, 1729-37	9.7	113
276	New therapies for castration-resistant prostate cancer: efficacy and safety. *European Urology*, **2011**, 60, 279-90	10.2	111
275	Pazopanib: Clinical development of a potent anti-angiogenic drug. *Critical Reviews in Oncology/Hematology*, **2011**, 77, 163-71	7	111
274	Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. *Journal of Clinical Oncology* , **2007**, 25, 257-62	2.2	108
273	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. *European Urology*, **2015**, 67, 100-110	10.2	106
272	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. *Lancet Oncology, The*, **2010**, 11, 861-70	21.7	105
271	Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guﬂin: 18-year experience. *Urology*, **2002**, 59, 227-31	1.6	103
270	ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. *European Urology*, **2011**, 60, 684-90	10.2	100
269	Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. *British Journal of Urology*, **1989**, 64, 250-6		93
268	Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. *European Urology*, **1999**, 35, 52-6	10.2	91
267	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. *Clinical Cancer Research*, **2019**, 25, 3839-3846	12.9	90
266	Toxicities of targeted therapy and their management in kidney cancer. *European Urology*, **2011**, 59, 526-40	10.2	89
265	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. *European Urology*, **2013**, 63, 717-23	10.2	88
264	Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. *Urology*, **2011**, 77, 1166-71	1.6	78
263	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. *Critical Reviews in Oncology/Hematology*, **2010**, 73, 68-91	7	78
262	Castration-resistant prostate cancer: current and emerging treatment strategies. *Drugs*, **2010**, 70, 983-1000	4.1	77
261	Current therapies and advances in the treatment of pancreatic cancer. *Critical Reviews in Oncology/Hematology*, **2006**, 58, 231-41	7	76
260	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. *European Urology*, **2019**, 76, 73-81	10.2	74

259	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 525-537	21.7	73
258	Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. *Cancer*, **1991**, 68, 2561-5	6.4	72
257	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program **2019**, 7, 99		71
256	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. *Expert Opinion on Investigational Drugs*, **2008**, 17, 253-61	5.9	68
255	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1579-1587	2.2	68
254	Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. *European Urology*, **2009**, 55, 348-58	10.2	67
253	-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. *JCO Precision Oncology*, **2020**, 4, 370-381	3.6	66
252	Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. *Cancer*, **2009**, 115, 2652-9	6.4	64
251	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. *ESMO Open*, **2016**, 1, e000097	6	59
250	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. *European Urology*, **2016**, 70, 675-683	10.2	57
249	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. *Journal of Clinical Oncology*, **2021**, 39, 2474-2485	2.2	57
248	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 556-569	21.7	56
247	Sequelae of treatment in long-term survivors of testis cancer. *European Urology*, **2011**, 60, 516-26	10.2	56
246	Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. *BJU International*, **2013**, 111, 44-52	5.6	55
245	Novel molecular targets for the therapy of castration-resistant prostate cancer. *European Urology*, **2012**, 61, 950-60	10.2	54
244	Current indications for chemotherapy in prostate cancer patients. *European Urology*, **2007**, 51, 17-26	10.2	54
243	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. *Oncologist*, **2017**, 22, 667-679	5.7	50
242	Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. *Cancer*, **1993**, 72, 1975-82	6.4	50

241	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, 944-951	13.4	50
240	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. *European Urology*, **2018**, 74, 611-620	10.2	49
239	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. *Annals of Surgical Oncology*, **2015**, 22, 2094-100	3.1	48
238	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. *BJU International*, **2019**, 123, 98-105	5.6	48
237	Sequential use of targeted agents in the treatment of renal cell carcinoma. *Critical Reviews in Oncology/Hematology*, **2011**, 77, 48-62	7	48
236	Metastatic renal cell carcinoma: recent advances in the targeted therapy era. *European Urology*, **2009**, 56, 959-71	10.2	47
235	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. *Journal of Clinical Oncology*, **2012**, 30, LBA1-LBA1	2.2	44
234	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. *Journal of Clinical Oncology*, **2020**, 38, LBA1-LBA1	2.2	44
233	Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. *European Urology*, **2012**, 61, 307-16	10.2	43
232	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). *European Urology*, **2017**, 71, 281-289	10.2	41
231	Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. *Journal of Urology*, **1988**, 139, 475-7	2.5	41
230	Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. *Lancet Oncology, The*, **2014**, 15, 1263-8	21.7	40
229	The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. *European Urology*, **2011**, 60, 270-8	10.2	39
228	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. *European Urology*, **2017**, 71, 168-171	10.2	38
227	Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. *Cancer*, **2013**, 119, 3610-8	6.4	38
226	Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. *Clinical Cancer Research*, **2018**, 24, 3005-3013	12.9	37
225	The management of stage I testis cancer. *Urologic Clinics of North America*, **1998**, 25, 435-49	2.9	37
224	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. *Clinical Genitourinary Cancer*, **2020**, 18, 284-294	3.3	37

223	Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. *Current Drug Targets*, **2015**, 16, 164-70	3	36
222	Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. *Critical Reviews in Oncology/Hematology*, **2007**, 61, 176-85	7	35
221	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 105-120	21.7	35
220	Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-Β ligand inhibitors in patients with advanced prostate cancer. *European Urology*, **2014**, 65, 278-86	10.2	34
219	Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. *Drug Design, Development and Therapy*, **2015**, 9, 3325-39	4.4	33
218	Numeric definition of the clinical performance of the nested reverse transcription-PCR for detection of hematogenous epithelial cells and correction for specific mRNA of non-target cell origin as evaluated for prostate cancer cells. *Clinical Chemistry*, **2003**, 49, 1458-66	5.5	33
217	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. *Targeted Oncology*, **2015**, 10, 517-22	5	32
216	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, 694-701	13.4	32
215	New drugs and new approaches for the treatment of metastatic urothelial cancer. *World Journal of Urology*, **2002**, 20, 158-66	4	30
214	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.. *New England Journal of Medicine*, **2022**,	59.2	30
213	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. *BJU International*, **2014**, 113, E137-43	5.6	28
212	The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. *Cancer Treatment Reviews*, **2018**, 68, 25-37	14.4	27
211	A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. *Annals of Nuclear Medicine*, **2016**, 30, 163-8	2.5	27
210	Clinical and pharmacokinetic evaluation of satraplatin. *Expert Opinion on Drug Metabolism and Toxicology*, **2012**, 8, 103-11	5.5	27
209	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. *Lancet, The*, **2021**, 398, 131-142	40	27
208	Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. *Clinical Genitourinary Cancer*, **2014**, 12, 130-7	3.3	26
207	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. *JAMA Oncology*, **2017**, 3, 68-75	13.4	26
206	Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. *BJU International*, **2012**, 109, 200-6	5.6	26

205	The medical management of prostate cancer: a multidisciplinary team approach. *BJU International*, **2007**, 99, 22-7	5.6	26
204	Satraplatin in the treatment of hormone-refractory prostate cancer. *BJU International*, **2005**, 96, 990-4	5.6	26
203	Bladder cancer. *Critical Reviews in Oncology/Hematology*, **2002**, 41, 89-106	7	24
202	Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?. *Critical Reviews in Oncology/Hematology*, **2005**, 55, 67-81	7	24
201	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. *Future Oncology*, **2019**, 15, 929-941	3.6	23
200	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. *Oncologist*, **2015**, 20, 1028-35	5.7	22
199	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clinical Genitourinary Cancer*, **2018**, 16, e945-e951	3.3	22
198	The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. *European Urology*, **2012**, 61, 1212-21	10.2	22
197	Reducing the burden of bone metastases: current concepts and treatment options. *Supportive Care in Cancer*, **2013**, 21, 1773-83	3.9	22
196	Role of targeted therapy in the treatment of advanced prostate cancer. *BJU International*, **2010**, 105, 748-67	5.6	22
195	Neoadjuvant systemic therapy for urological malignancies. *BJU International*, **2010**, 106, 6-22	5.6	21
194	Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. *BJU International*, **2008**, 102, 1607-9	5.6	21
193	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. *JAMA Oncology*, **2019**, 5, 1159-1167	13.4	19
192	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. *Critical Reviews in Oncology/Hematology*, **2015**, 95, 133-43	7	19
191	High-risk metastatic urothelial cancer: chances for cure?. *Current Opinion in Urology*, **2002**, 12, 441-8	2.8	19
190	Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. *Cancer Chemotherapy and Pharmacology*, **1986**, 18, 24-6	3.5	19
189	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. *Journal of Clinical Oncology*, **2021**, 39, 1563-1574	2.2	19
188	Accelerating precision medicine in metastatic prostate cancer. *Nature Cancer*, **2020**, 1, 1041-1053	15.4	18

187	Highlights of contemporary issues in the medical management of prostate cancer. *Critical Reviews in Oncology/Hematology*, **2002**, 43, 105-21	7	17
186	Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. *Investigational New Drugs*, **1990**, 8, 391-2	4.3	17
185	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. *European Urology Oncology*, **2020**, 3, 94-101	6.7	17
184	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. *Frontiers in Oncology*, **2018**, 8, 463	5.3	17
183	Neoadjuvant chemotherapy for invasive bladder cancer. *Current Urology Reports*, **2012**, 13, 136-46	2.9	16
182	Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. *Expert Opinion on Drug Safety*, **2012**, 11, 851-9	4.1	16
181	New treatment approaches in metastatic renal cell carcinoma. *Current Opinion in Urology*, **2006**, 16, 337-41	1.8	16
180	Neo-adjuvant chemotherapy in invasive bladder cancer. *World Journal of Urology*, **2001**, 19, 94-8	4	15
179	Transurethral resection of the prostate and metastatic prostate cancer. *Cancer*, **1991**, 68, 1895-8	6.4	15
178	Fine flutterings of the aortic valve as demonstrated by aortic valve echocardiograms. *American Heart Journal*, **1978**, 95, 807-8	4.9	15
177	FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression.. *Journal of Clinical Oncology*, **2020**, 38, 489-489	2.2	15
176	Optimizing outcomes at every stage of bladder cancer: do we practice it?. *Urologic Oncology: Seminars and Original Investigations*, **2009**, 27, 72-4	2.8	14
175	Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. *BJU International*, **2008**, 102, 1354-60	5.6	14
174	Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. *Future Oncology*, **2019**, 15, 1437-1457	3.6	13
173	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. *Cancer Treatment Reviews*, **2020**, 88, 102057	14.4	13
172	Differences in depressive thoughts between major depressive disorder, IFN-alpha-induced depression, and depressive disorders among cancer patients. *Journal of Psychosomatic Research*, **2008**, 65, 153-6	4.1	13
171	State-of-the-art management of metastatic disease at initial presentation or recurrence. *World Journal of Urology*, **2006**, 24, 543-56	4	13
170	Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1987**, 10, 219-21	2.7	13

169	Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. *Translational Andrology and Urology*, **2015**, 4, 355-64	2.3	13
168	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. *Lancet Oncology, The*, **2020**, 21, 1513-1525	21.7	13
167	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. *Journal of Clinical Oncology*, **2021**, 39, 1553-1562	2.2	13
166	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. *ESMO Open*, **2020**, 5,	6	12
165	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. *World Journal of Urology*, **2019**, 37, 95-105	4	12
164	Enzalutamide in European and North American men participating in the AFFIRM trial. *BJU International*, **2015**, 115, 41-9	5.6	11
163	Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. *BJU International*, **2006**, 97, 435-8	5.6	11
162	What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?. *BJU International*, **2006**, 98, 487-9	5.6	11
161	Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. *Current Opinion in Urology*, **2001**, 11, 523-9	2.8	11
160	Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder. *Urologic Oncology: Seminars and Original Investigations*, **1995**, 1, 127-33	2.8	11
159	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. *European Urology*, **2021**, 79, 334-338	10.2	11
158	Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. *European Urology Oncology*, **2019**, 2, 677-684	6.7	10
157	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. *European Urology*, **2019**, 76, 425-429	10.2	10
156	Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. *BJU International*, **2012**, 110, 1289-300	5.6	10
155	Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. *Seminars in Oncology*, **2007**, 34, 122-8	5.5	10
154	Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).. *Journal of Clinical Oncology*, **2020**, 38, 5515-5515	2.2	10
153	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. *JAMA Oncology*, **2020**, 6, 217-225	13.4	10
152	Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. *European Journal of Cancer*, **2020**, 138, 202-211	7.5	10

151	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. *European Urology Oncology*, **2020**, 3, 176-182	6.7	10
150	Pazopanib in renal cell carcinoma. *Clinical Advances in Hematology and Oncology*, **2010**, 8, 232-3	0.6	10
149	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 680-688	6.2	9
148	Novel agents for muscle-invasive and advanced urothelial cancer. *BJU International*, **2008**, 101, 937-43	5.6	9
147	Signal-transduction inhibitors in renal cell carcinoma. *BJU International*, **2007**, 99, 1289-95	5.6	9
146	Chemotherapy for local treatment of bladder cancer. *Seminars in Radiation Oncology*, **2005**, 15, 60-5	5.5	9
145	Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program. *European Journal of Cancer & Clinical Oncology*, **1989**, 25, 753-4		9
144	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. *Cancer Treatment Reviews*, **2021**, 97, 102187	14.4	9
143	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. *European Urology Focus*, **2016**, 2, 480-487	5.1	9
142	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, 425-435.e4	3.3	9
141	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. *European Urology Oncology*, **2019**, 2, 248-256	6.7	9
140	Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. *Clinical Genitourinary Cancer*, **2014**, 12, 262-9	3.3	8
139	What's new in the treatment of metastatic kidney cancer?. *BJU International*, **2005**, 95, 1171-80	5.6	8
138	Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.. *Journal of Clinical Oncology* , **2019**, 37, 256-256	2.2	8
137	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. *European Urology*, **2021**, 79, 519-529	10.2	8
136	Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. *Critical Reviews in Oncology/Hematology*, **2016**, 106, 14-24	7	7
135	Contemporary management of metastatic castration-resistant prostate cancer. *Current Opinion in Urology*, **2011**, 21, 241-7	2.8	7
134	The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. *International Journal of Urology*, **2010**, 17, 228-40	2.3	7

133	Satraplatin for the therapy of castration-resistant prostate cancer. *Future Oncology*, **2009**, 5, 931-40	3.6	7
132	Metastatic bladder cancer: anything new?. *Current Opinion in Supportive and Palliative Care*, **2012**, 6, 304-9	2.6	7
131	Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. *Radiotherapy and Oncology*, **1995**, 35, 123-8	5.3	7
130	Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1988**, 11, 172-3	2.7	7
129	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. *Oncologist*, **2019**, 24, 1348-1355	5.7	7
128	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. *JCO Precision Oncology*, **2019**, 3,	3.6	7
127	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. *European Urology Oncology*, **2020**, 3, 671-679	6.7	7
126	PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2021**, 39, 13-13	2.2	7
125	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. *European Urology Focus*, **2018**, 4, 937-945	5.1	6
124	Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2012**, 35, 493-7	2.7	6
123	Second-line chemotherapy in advanced bladder cancer. *Urologia Internationalis*, **2000**, 64, 61-9	1.9	6
122	Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients. *European Urology*, **2001**, 39, 430-7	10.2	6
121	A critical review of the management of bladder cancer. *Critical Reviews in Oncology/Hematology*, **1999**, 31, 193-207	7	6
120	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. *Nature Medicine*, **2021**,	50.5	6
119	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2020**, 38, 182-182	2.2	6
118	Common germline-somatic variant interactions in advanced urothelial cancer. *Nature Communications*, **2020**, 11, 6195	17.4	6
117	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. *European Urology Focus*, **2019**, 5, 242-249	5.1	6
116	Novel targeted therapy for advanced renal carcinoma: trials in progress. *Current Opinion in Urology*, **2010**, 20, 382-7	2.8	5

115	Metastatic Bladder Cancer: Role of Chemotherapy and New Agents. *EAU Update Series*, **2003**, 1, 108-117		5
114	Phase II evaluation of m-AMSA (4P(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1983**, 6, 459-62	2.7	5
113	Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.. *Journal of Clinical Oncology*, **2021**, 39, 438-438	2.2	5
112	Management of good risk germ-cell tumours. *BJU International*, **2009**, 104, 1387-91	5.6	4
111	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. *European Urology Supplements*, **2009**, 8, 738-746	0.9	4
110	Localized and locally advanced bladder cancer. *Current Treatment Options in Oncology*, **2002**, 3, 413-28	5.4	4
109	Bladder preservation--a prospect for patients with urinary bladder cancer. *Acta Oncologica*, **1995**, 34, 589-97; discusion 588	3.2	4
108	Phase II trial of 10 deaza-aminopterin in patients with bladder cancer. *Investigational New Drugs*, **1986**, 4, 171-4	4.3	4
107	Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. *European Urology*, **2021**, 81, 50-50	10.2	4
106	Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2021**, 39, 5015-5015	2.2	4
105	Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. *BJU International*, **2007**, 100, 533-5	5.6	3
104	Phase I/II trial of intravesical methotrexate for superficial bladder tumors. *Cancer Chemotherapy and Pharmacology*, **1986**, 18, 265-9	3.5	3
103	Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1988**, 11, 174-6	2.7	3
102	Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2019**, 37, 253-253	2.2	3
101	TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.. *Journal of Clinical Oncology*, **2019**, 37, TPS495-TPS495	2.2	3
100	Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.. *Journal of Clinical Oncology*, **2020**, 38, 16-16	2.2	3
99	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.. *Journal of Clinical Oncology*, **2021**, 39, 4527-4527	2.2	3
98	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. *European Urology*, **2021**, 80, 497-506	10.2	3

97	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. *Clinical Cancer Research*, **2021**,	12.9	3
96	Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. *European Urology*, **2016**, 69, 1155-6	10.2	2
95	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. *Update on Cancer Therapeutics*, **2009**, 3, 133-145		2
94	Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. *Nature Reviews Urology*, **2008**, 5, 422-3		2
93	Cancer and its Management. *BJU International*, **2006**, 97, 651-651	5.6	2
92	Overview of international collaborative group prostate cancer trials. *Critical Reviews in Oncology/Hematology*, **2002**, 43, 153-8	7	2
91	Adjuvant chemotherapy for bladder cancer. *Expert Review of Anticancer Therapy*, **2005**, 5, 987-92	3.5	2
90	Phase II trial of 1,2-diaminocyclohexane-(4-carboxyphthalato) platinum(II) (DACCP) in colorectal carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1984**, 7, 503-5	2.7	2
89	MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1984**, 7, 529-33	2.7	2
88	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. *European Journal of Cancer*, **2021**, 159, 237-246	7.5	2
87	Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. *European Urology*, **2020**, 78, 847-853	10.2	2
86	Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. *JCO Precision Oncology*, **2021**, 5,	3.6	2
85	Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. *Translational Oncology*, **2021**, 14, 100944	4.9	2
84	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. *European Urology*, **2022**,	10.2	2
83	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. *Clinical Cancer Research*, **2022**,	12.9	2
82	Is there a role for presurgical therapy for renal cell carcinoma?. *Expert Review of Anticancer Therapy*, **2010**, 10, 807-12	3.5	1
81	An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. *Frontiers in Oncology*, **2012**, 2, 175	5.3	1
80	Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum. *European Urology Supplements*, **2009**, 8, 733-737	0.9	1

79	Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **1997**, 3, 133-40	2.8	1
78	Molecular pathways and the hope of targeting angiogenesis. *Nature Reviews Urology*, **2007**, 4, 470-1		1
77	The evolving role of chemotherapy in advanced urothelial cancer. *Current Opinion in Supportive and Palliative Care*, **2007**, 1, 180-6	2.6	1
76	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. *British Journal of Cancer*, **2022**,	8.7	1
75	Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.. *Journal of Clinical Oncology*, **2019**, 37, 4519-4519	2.2	1
74	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. *Journal of Clinical Oncology*, **2020**, 38, 5559-5559	2.2	1
73	Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2020**, 38, 32-32	2.2	1
72	FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.. *Journal of Clinical Oncology*, **2020**, 38, TPS590-TPS590	2.2	1
71	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. *Kidney Cancer*, **2020**, 4, 29-39	0.6	1
70	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. *Japanese Journal of Clinical Oncology*, **2021**, 51, 1287-1297	2.8	1
69	Somatic and germline sequencing in genitourinary oncology: genetics for the clinician. *Current Opinion in Urology*, **2019**, 29, 315-318	2.8	1
68	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. *Journal of Clinical Oncology*, **2021**, 39, 120-120	2.2	1
67	Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).. *Journal of Clinical Oncology*, **2021**, 39, 101-101	2.2	1
66	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. *Oncologist*, **2021**, 26, 1026-1034	5.7	1
65	Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. *Journal of Urology*, **2021**, 206, 240-251	2.5	1
64	Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. *Oncologist*, **2021** , 26, e1971-e1981	5.7	1
63	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2022**, 40, 77-77	2.2	1
62	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2022**, 40, TPS216-TPS216	2.2	1

61	TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.. *Journal of Clinical Oncology*, **2022**, 40, 434-434	2.2	1
60	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. *Nature Communications*, **2022**, 13, 1878	17.4	1
59	Reply to S. Barni et Al and M. Sun et Al. *Journal of Clinical Oncology*, **2014**, 32, 3783-4	2.2	0
58	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. *European Journal of Cancer*, **2022**, 163, 55-65	7.5	0
57	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. *Future Oncology*, **2022**, 18, 35-45	3.6	0
56	A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.. *Journal of Clinical Oncology*, **2019**, 37, 185-185	2.2	0
55	Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.. *Journal of Clinical Oncology*, **2019**, 37, e16077-e16077	2.2	0
54	Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. *Journal of Clinical Oncology*, **2020**, 38, TPS606-TPS606	2.2	0
53	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. *Journal of Clinical Oncology*, **2020**, 38, 5569-5569	2.2	0
52	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 934.e1-934.e9	2.8	0
51	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. *European Urology Focus*, **2021**, 7, 1084-1091	5.1	0
50	PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.. *Journal of Clinical Oncology*, **2021**, 39, 84-84	2.2	0
49	Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).. *Journal of Clinical Oncology*, **2021**, 39, 94-94	2.2	0
48	Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.. *Journal of Clinical Oncology*, **2022**, 40, 13-13	2.2	0
47	TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).. *Journal of Clinical Oncology*, **2022**, 40, TPS581-TPS581	2.2	0
46	Clinical Trials Corner. *Bladder Cancer*, **2016**, 2, 469-471	1	
45	Clinical Trials Corner. *Bladder Cancer*, **2020**, 6, 93-95	1	
44	Clinical Trials Corner. *Bladder Cancer*, **2020**, 6, 219-221	1	

43	Pharmacotherapy options for advanced renal cell carcinoma. *Expert Opinion on Orphan Drugs*, **2014**, 2, 643-652	1.1
42	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. *Journal of Clinical Oncology*, **2014**, 32, 4172-3	2.2
41	Advances in the Management of Metastatic Renal Cell Cancer. *European Urology Supplements*, **2009**, 8, 758-761	0.9
40	The future of prostate cancer. *BJU International*, **2008**, 101, 934-6	5.6
39	Bladder cancer today. *BJU International*, **2008**, 102, 1203	5.6
38	Novel treatment options for refractory germ cell tumors. *Update on Cancer Therapeutics*, **2008**, 3, 89-96	
37	Development of novel agents and combinations for renal carcinoma. *Update on Cancer Therapeutics*, **2008**, 3, 97-103	
36	A new era in prostate cancer therapy: new targets and novel therapeutics. *Targeted Oncology*, **2008**, 3, 31-39	5
35	Adjuvant bicalutamide for early prostate cancer: an update. *Nature Reviews Urology*, **2006**, 3, 408-9	
34	Introduction: A multidisciplinary approach to genitourinary malignancy: does this topic warrant further debate?. *Nature Reviews Urology*, **2007**, 4, S1-S2	
33	Clinical Trials Corner Issue 8(1). *Bladder Cancer*, **2022**, 1-3	1
32	Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2020**, 38, 50-50	2.2
31	Serial circulating tumor DNA (ctDNA) measurement to predict progression in patients (pts) with advanced urothelial carcinoma (aUC).. *Journal of Clinical Oncology*, **2020**, 38, 558-558	2.2
30	Clinical Trials Corner Issue 7(4). *Bladder Cancer*, **2021**, 1-4	1
29	Clinical Trials Corner Issue 6(3). *Bladder Cancer*, **2020**, 6, 395-398	1
28	The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2019**, 37, 183-183	2.2
27	External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2019**, 37, 5022-5022	2.2
26	Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 5073-5073	2.2

25	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. *Journal of Clinical Oncology*, **2019**, 37, e16017-e16017	2.2
24	Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2019**, 37, 5021-5021	2.2
23	Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. *Journal of Clinical Oncology*, **2020**, 38, TPS5096-TPS5096	2.2
22	Clinical Trials Corner Issue 6(4). *Bladder Cancer*, **2020**, 6, 553-556	1
21	Muscle-invasive transitional cell carcinoma of the bladder: strategies for bladder preservation. *Current Opinion in Urology*, **1998**, 8, 431-5	2.8
20	Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.. *Journal of Clinical Oncology*, **2021**, 39, TPS5095-TPS5095	2.2
19	Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).. *Journal of Clinical Oncology*, **2021**, 39, 5040-5040	2.2
18	Clinical Trials Corner Issue 7(2). *Bladder Cancer*, **2021**, 7, 257-260	1
17	Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).. *Journal of Clinical Oncology*, **2021**, 39, 5055-5055	2.2
16	Clinical Trials Corner. *Bladder Cancer*, **2019**, 5, 83-84	1
15	Clinical Trials Corner. *Bladder Cancer*, **2019**, 5, 185-187	1
14	Clinical Trials Corner. *Bladder Cancer*, **2019**, 5, 309-311	1
13	A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2021**, 39, TPS188-TPS188	2.2
12	Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2021**, 39, 140-140	2.2
11	Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens.. *Journal of Clinical Oncology*, **2021**, 39, 459-459	2.2
10	An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).. *Journal of Clinical Oncology*, **2021**, 39, 429-429	2.2
9	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2021**, 39, 158-158	2.2
8	Clinical Trials Corner Issue 7(1). *Bladder Cancer*, **2021**, 7, 103-106	1

7	Clinical Trials Corner. *Bladder Cancer*, **2018**, 4, 447-449	1
6	Clinical Trials Corner Issue 7(3). *Bladder Cancer*, **2021**, 7, 381-384	1
5	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. *Journal of Clinical Oncology*, **2022**, 40, 532-532	2.2
4	PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.. *Journal of Clinical Oncology*, **2022**, 40, TPS578-TPS578	2.2
3	Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.. *Journal of Clinical Oncology*, **2022**, 40, 512-512	2.2
2	Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.. *Journal of Clinical Oncology*, **2022**, 40, 37-37	2.2
1	Clinical Trials Corner Issue 8(2). *Bladder Cancer*, **2022**, 1-3	1